Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Objective To determine whether specific patterns of [ 18 F]-AV-1451 tau-PET retention are observed in patients with autopsy-proven sporadic Creutzfeldt-Jakob disease (CJD). Methods In vivo [ 18 F]-AV-1451 PET neuroimaging was performed in 5 patients with sporadic CJD (median age, 66 years [63-74]), and results were compared to cognitively normal (CN) persons (n = 44; median age, 68 years [63-74]) and to participants with very mild Alzheimer disease (AD) dementia (n = 8; median age, 77 years [63-90]). Autopsy was completed in all patients with CJD, confirming the clinical diagnosis and permitting characterization of AD neuropathologic change (ADNC).

What this study adds

Evidence grade: Low

The record lists 44 participants. This small imaging study of 5 patients with autopsy-confirmed Creutzfeldt-Jakob disease found tau-PET patterns that differed from Alzheimer's disease. It is about distinguishing these diseases on scans, not about treating or preventing Alzheimer's.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Day, G. S., Gordon, B. A., Perrin, R. J., Cairns, N. J., Beaumont, H., Schwetye, K., et al. (2018). In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology. https://doi.org/10.1212/wnl.0000000000005064

Vancouver

Day GS, Gordon BA, Perrin RJ, Cairns NJ, Beaumont H, Schwetye K, et al. In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology. 2018. doi:10.1212/wnl.0000000000005064. PMID: 29438042.

BibTeX

@article{day2018-29438042,
  author  = {Day, G. S. and Gordon, B. A. and Perrin, R. J. and Cairns, N. J. and Beaumont, H. and Schwetye, K. and Ferguson, C. and Sinha, N. and others},
  title   = {{In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease}},
  journal = {Neurology},
  year    = {2018},
  doi     = {10.1212/wnl.0000000000005064},
  pmid    = {29438042},
  url     = {https://doi.org/10.1212/wnl.0000000000005064}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This small imaging study of 5 patients with autopsy-confirmed Creutzfeldt-Jakob disease found tau-PET patterns that differed from Alzheimer's disease. It is about distinguishing these diseases on scans, not about treating or preventing Alzheimer's.

Study details

How this study scored 45/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 44 of the 97 points it could be judged on, which is 45 of 100. Total 45 of 100.44 of the 97 points we could judge = 45 of 100

Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 44 of the 97 points we could judge it on, which is 45 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 1 / 4 44 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 26 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.6 citations a year over 10 year(s) since 2018
Impact for its field and year 2 / 6 Cited 1.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 3 other studies in this library
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Beau M. Ances: h-index 81 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 29438042)
Free to read 0 / 2 Behind a paywall — scores zero
Points 44 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 44 of the 97 points we could judge it on is 45 out of 100.
Total 45 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers from nearby years

Also tagged “phosphorylated”

733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →